Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Condition:   Metastatic Pancreatic Ductal Adenocarcinoma Interventions:   Drug: Relacorilant, 100 mg and 25 mg;   Drug: Nab paclitaxel Sponsor:   Corcept Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials